Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
批准号:
9551298
负责人:
Na Yang
金额:
$245.31万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
BloodCalciumCataractChronicClinicalClinical TrialsCollaborationsConvulsionsDataDevelopment PlansDoseDrug KineticsEquilibriumGoalsHeart AbnormalitiesHypercalcemiaHypocalcemia resultHypoparathyroidismIntellectual functioning disabilityInvestigational New Drug ApplicationLengthModelingMuscle CrampPTH geneParathyroid Hormone ReceptorPatientsPhasePreparationPropertyRattusResearch PersonnelRoleScientistSerumSymptomsSyndromeTherapeutics for Rare and Neglected Diseasescalcium phosphateheart rhythmhormone analoghormone deficiencypreclinical development
中文摘要
甲状旁腺功能减退的主要症状包括肌肉痉挛、抽搐、智力障碍、白内障和心律异常。症状是由于低血清钙(低钙血症)。已探索替代甲状旁腺激素(PTH)来治疗钙缺乏症,但事实证明,维持最佳钙水平存在问题,因为过量的甲状旁腺激素可能会导致高钙血症。目前正在进行多种努力,靶向全长PTH(PTH 184)或活性氨基末端结构域(PTH 134),但这些分子对于甲状旁腺功能减退患者的钙水平的长期日常管理具有不良的药代动力学特性。
礼来公司的科学家已经确定了一种长效甲状旁腺素受体调节剂(PTH-RM),可以使血清钙正常化。在相当低的剂量下,PTH-RM显示出使甲状旁腺切除大鼠的钙水平正常化。研究人员正在与TRND合作,通过利用现有的数据包,将PTH-RM开发为甲状旁腺功能减退症的II期概念验证研究。
TRND的科学家与礼来公司的研究人员合作,进一步开发和验证了甲状旁腺功能减退症的大鼠模型,以生成可靠的疗效数据。该团队将执行完整的临床前开发计划。TRND将支持研究性新药申请的准备和向FDA提交,并与临床专家合作,为后续的患者临床试验提供支持。
英文摘要
The primary symptoms of hypoparathyroidism include muscle cramping, convulsions, intellectual disabilities, cataracts and abnormal heart rhythm. Symptoms are due to low serum calcium (hypocalcemia). Replacement of parathyroid hormone (PTH) has been explored to remedy the calcium deficiency, but maintaining an optimal calcium level has proven problematic because hypercalcemia can occur as a result of excess PTH. Multiple efforts are under way targeting either full-length PTH (PTH 184) or the active amino-terminal domain (PTH 134), but these molecules have undesirable pharmacokinetic properties for chronic daily management of calcium levels in patients with hypoparathyroidism.
Eli Lilly scientists have identified a long acting PTH receptor modulator (PTH-RM) that can normalize serum calcium. At fairly low doses, the PTH-RM was shown to normalize calcium levels in parathyroidectomized rats. The investigators are collaborating with TRND to develop this PTH-RM toward a Phase II proof-of-concept study for hypoparathyroidism by leveraging the existing data package.
TRND scientists, in collaboration with researchers from Eli Lilly & Company, have further developed and validated the rat model of hypoparathyroidism to generate robust efficacy data. The team will execute the full preclinical development plan. TRND will support the preparation and filing of the Investigational New Drug application with the FDA, partnering with clinical experts to support for subsequent clinical trials in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
-
批准号:9354957
-
项目类别:
-
资助金额:$176.51万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Long-Acting Parathyroid Hormone Analog for the Treatment of Hypoparathyroidism
-
批准号:9205575
-
项目类别:
-
资助金额:$200.38万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Gene Therapy Platform for Rare Diseases
-
批准号:9551937
-
项目类别:
-
资助金额:$205.31万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
Gene Therapy Platform for Rare Diseases
-
批准号:10004998
-
项目类别:
-
资助金额:$322.87万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
DEX-M74 for GNE Myopathy
-
批准号:9205573
-
项目类别:
-
资助金额:$200.38万
-
财政年份:--
-
负责人:Na Yang
-
依托单位:
国内基金
海外基金
Calcium/NFAT/GLUT3通路调控糖酵解代谢在CAR-T细胞耗竭中的作用和机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:张明明
-
依托单位:
miR-30调控Calcium/Calcineurin通路在慢性肾脏病心肌保护中的作用
-
批准号:81670699
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:郑春霞
-
依托单位:
水稻OsCAS(Calcium-sensing Receptor)基因的功能分析
-
批准号:30900771
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2009
-
负责人:赵昕
-
依托单位: